JMP reiterates Oscient at market outperform

Oscient Pharmaceuticals Corp. was reiterated at market outperform by JMP Securities analyst Adam Cutler. The analyst continues to track weekly Factive and Testim prescription volumes using NDC Health data. For the week ended March 10, NDC reported that Factive total prescriptions were 11,568 (11,316 new), or 1.54% of weekly prescriptions for the quinolone class of antibiotics. This compares with 11,213 total prescriptions (10,954 new) in the previous week, or 1.47% of weekly prescriptions from the quinolone class. Through March 10, an approximate 88,556 Factive prescriptions have been written in the first quarter, generating about $7.9 million in revenue. Total Testim scripts for the week ended March 10 were 5,400, compared with the previous week's total of 5,341. Shares of the Waltham, Mass., pharmaceutical company were up 7 cents, or 3.45%, at $2.10 on volume of 533,517 shares versus the three-month running average of 603,438 shares. (Nasdaq: OSCI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.